Meta Information

ID:dapagliflozin

Name:Dapagliflozin

Schema Version:1.5

Alternate Names

• Farxiga

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:

10

High Cost:

600

Cost Type:

monthly

Description:

Varies widely based on insurance coverage and generic vs. brand name availability.

Summary

Dapagliflozin is an SGLT2 inhibitor that causes the kidneys to excrete excess glucose, lowering blood sugar and blood pressure. Its healthspan relevance stems from robust clinical trial data showing profound protection against heart failure and chronic kidney disease progression, even in non-diabetic individuals. This suggests it addresses fundamental aging pathways related to metabolic stress and inflammation beyond simple glucose control.

Purpose

SGLT2 inhibitor for cardiorenal protection and metabolic health optimization.

Card Summary

An SGLT2 inhibitor that lowers blood glucose and provides significant heart and kidney protection.

Drug Class

sglt2-inhibitors

Drugs In Class

Empty Array

Impact

Score:

7.8

Justification:

Strong evidence for major organ protection (heart, kidney) beyond glucose control.

Evidence

Grade:

A

Score:

9.5

Justification:

Multiple large-scale human RCTs demonstrate robust cardiorenal benefits in diverse populations.

Safety

Score:

5.5

Justification:

Generally well-tolerated but carries risks of GU infections and rare ketoacidosis.

Flags

• Increased risk of genital yeast infections and urinary tract infections is common.
• Rare but serious risk of euglycemic diabetic ketoacidosis (DKA), even with normal blood sugar.
• May cause dehydration and hypotension; adequate fluid intake is important.
• Not recommended for individuals with severe kidney impairment (low eGFR).
• Potential for Fournier's gangrene, a rare but serious genital infection.

Verdict

A powerful tool for cardiorenal protection, especially with metabolic dysfunction.

Created

2026-04-27T01:02:54.865161Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:

oral

Scope:

• systemic

Indication

Focus:

disease_treatment

Description:

Dapagliflozin is an SGLT2 inhibitor that causes the kidneys to excrete excess glucose, lowering blood sugar and blood pressure. Its healthspan relevance stems from robust clinical trial data showing p...

Typical Protocol

• Take one 5mg or 10mg tablet orally once daily, typically in the morning.